Evidence map›Paper›PMID 39044816›Full record

ArticleFrontiers in immunology2024

Case report: Persistent hypogammaglobulinemia and mixed chimerism after HLA class-II disparate-hematopoietic stem cell transplant.

Melanie de Gier, Ingrid Pico-Knijnenburg, Monique M van Ostaijen-Ten Dam, Dagmar Berghuis, Frans J Smiers, Adriaan A van Beek, Hetty Jolink, Patty M Jansen, Arjan C Lankester, Mirjam van der Burg

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Melanie de GierDepartment of Pediatrics, Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Ingrid Pico-KnijnenburgDepartment of Pediatrics, Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Monique M van Ostaijen-Ten DamDepartment of Pediatrics, Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Dagmar BerghuisDepartment of Pediatrics, Division of Pediatric Immunology, Hematology and Stem Cell Transplantation, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Frans J SmiersDepartment of Pediatrics, Division of Pediatric Immunology, Hematology and Stem Cell Transplantation, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Adriaan A van BeekHLA Laboratory, Department of Immunology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Hetty JolinkDepartment of Infectious Diseases, Leiden University Center of Infectious Diseases (LU-CID), Leiden University Medical Center (LUMC), Leiden, Netherlands.
Patty M JansenDepartment of Pathology, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Arjan C LankesterDepartment of Pediatrics, Division of Pediatric Immunology, Hematology and Stem Cell Transplantation, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.
Mirjam van der BurgDepartment of Pediatrics, Laboratory for Pediatric Immunology, Willem-Alexander Children's Hospital, Leiden University Medical Center (LUMC), Leiden, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for various hematological, immunological and metabolic diseases, replacing the patient's hematopoietic system with donor-derived healthy hematopoietic stem cells. HSCT can be complicated by early and late events related to impaired immunological recovery such as prolonged hypogammaglobulinemia post-HSCT. We present a 16-year-old female patient with sickle-cell disease who underwent HSCT with stem cells from a human leukocyte antigen (HLA) class-II mismatched family donor. While cellular recovery was good post-HSCT, the patient developed mixed chimerism and suffered from cervical lymphadenopathy, recurrent airway infections and cutaneous SLE. She presented with hypogammaglobulinemia and was started on immunoglobulin substitution therapy and antibiotic prophylaxis. B-cell phenotyping showed that she had increased transitional and naïve mature B cells, reduced memory B cells, and diminished marginal zone/natural effector cells. In-depth immunophenotyping and B-cell receptor repertoire sequencing ruled out an intrinsic B-cell defect by expression of activation-induced cytidine deaminase (AID), presence of somatic hypermutations and differentiation into IgG- and IgA-producing plasma cells

Indexed as

AgammaglobulinemiaHematopoietic Stem Cell TransplantationAdolescentAnemia, Sickle CellB-LymphocytesFemaleHLA AntigensHumansTransplantation ChimeraHLA Antigensallogeneic hematopoietic stem-cell transplant (HSCT)B-cell phenotypingB-cell receptor repertoireHLA class-IIhypogammaglobulinemiamixed chimerism

Identifiers

PMID39044816
PMCPMC11263073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.